Livewire Ergogenics, Inc. Announces Strategic Development Agreements and Appointments to Advisory Board
ANAHEIM, CA--(Marketwired - Jul 25, 2017) - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research
partnerships, product development and commercialization of cannabinoid-based products, today announced it has entered into
development agreements with seasoned horticulturists Kyle McKay and Jason Olson. The company also announced their appointments to
the newly formed "7xPure" Advisory and Compliance Board.
Mr. McKay and Mr. Olson will be responsible for providing extensive cultivation expertise specifically in cannabis cloning to
provide proven and newly developed strains for research study purposes and potential commercial development. Under the terms of
the development agreements, they will identify new varieties of cannabis strains in an effort to provide greater efficacy when
targeting specific ailments. Together, they possess over 25 years of experience in the industry and are extremely qualified to
guide LiveWire's efforts to become a significant force in the cannabinoid health and wellness industry. Their expertise in plant
genetics and modern horticulture technology, in combination with their track record of growing successful strains, makes them
extremely qualified to render the requisite services to Company
Bill Hodson, CEO of LiveWire Ergogenics, states, "Kyle and Jason may be two of the most qualified developers I have met in
this space. They perfectly fit our strategy to advance our developments with an experienced and highly regarded team with
specific disciplines to continue expanding our vertically integrated network. We are aggressively positioning ourselves to take
advantage of new and commercially viable opportunities, initially in the California cannabis space, with plans to expand. This
includes cloning, grow facilities, extraction and distribution, all of which feeds our passion for innovative and high-quality
product development that will accelerate the building of a sustainable and profitable business in a new and burgeoning cannabis
market."
Messrs. McKay and Olson will also serve on the Livewire Scientific Advisory Board currently being formed. Their passion for
pesticide-free, clean genetics and organic growth is also expected to be a driving force in establishing the strict testing
requirements for LiveWire's "7xPure Compliance and Verification System" currently in development. Livewire strives to establish
its "7xPure" Compliance and Verification System as the gold standard for the entire industry.
About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) is focused on identifying and monetizing current and future trends in the health
and wellness industry, derived from, or enhanced with legal cannabis products. The Company is focused on establishing and
advancing research partnerships for specific ailments, cloning of high-quality and organic cannabis strains to effectively
address these ailments, dosing verification of zero pesticide products for quality brands and the general development and
commercialization of cannabinoid based products and services. The team at LiveWire Ergogenics is committed to developing
high-quality and organically clean products and generate and execute innovative ideas for the advancement of the company, its
customers and the entire industry.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and
objectives of management for future operations, the development, regulatory approvals and commercialization of the Company's
products, or any of the Company's other proposed products, systems or services. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or circumstances and actual results may differ considerably. Factors
that may cause actual results to differ materially from any projections or outlooks may include, without limitation, the
Company's inability to obtain additional financing to continue operations, delays in the development of its products, the impact
of significant government regulation in the cannabis industry, existing or increased competition, results of arbitration and
litigation, stock volatility and illiquidity, and the Company's failure in general to implement the Company's business plans or
strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that
may arise after the date of this release.